Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.44 |
| ▸ | BRD4 | O60885 | 5/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | PLK4 | O00444 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | INSR | P06213 | 2/20 | 0.39 |
| ▸ | IGF1R | P08069 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | FLT4 | P35916 | 2/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | TEK | Q02763 | 2/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1543040 | 0.87 | CYP3A4 (0.55) | CYP3A4PDGFRBBRD4CYP1A1EGFR | |
| SCHEMBL2128598 | 0.86 | CYP3A4 (0.54) | CYP3A4PDGFRBCYP1A1EGFRABL1 | |
| SCHEMBL2128925 | 0.86 | CYP3A4 (0.54) | CYP3A4PDGFRBCYP1A1AURKAEGFR | |
| SCHEMBL1542385 | 0.85 | CYP3A4 (0.64) | CYP3A4PDGFRBCYP1A1EGFRABL1 | |
| SCHEMBL1543223 | 0.84 | CYP3A4 (0.47) | CYP3A4PDGFRBCYP1A1EGFRERBB2 | |
| SCHEMBL2128919 | 0.83 | CYP3A4 (0.52) | CYP3A4CYP1A1EGFRABL1ERBB2 | |
| SCHEMBL12678795 | 0.82 | CYP3A4 (0.66) | CYP3A4PDGFRBBRD4CYP1A1EGFR | |
| SCHEMBL12678828 | 0.82 | CYP3A4 (0.61) | CYP3A4PDGFRBCYP1A1EGFRABL1 | |
| SCHEMBL1542980 | 0.80 | CYP3A4 (0.49) | CYP3A4EGFRABL1ERBB2 | |
| SCHEMBL1543433 | 0.80 | CYP3A4 (0.61) | CYP3A4BRD4EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | claimed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | claimed |
| EP-2307372-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | claimed |
| WO-2010010017-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-28 | — | — | WO | claimed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | CYP3A4 528/4885PDGFRB 627/4885BRD4 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.